Invention Grant
- Patent Title: Triazolones and tetrazolones as inhibitors of ROCK
-
Application No.: US16098978Application Date: 2017-05-26
-
Publication No.: US10562887B2Publication Date: 2020-02-18
- Inventor: Natesan Murugesan , Peter W. Glunz , Mandar Shrikrishna Bodas , Navnath Dnyanoba Yadav , Venu Alla
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Hong Liu
- International Application: PCT/US2017/034613 WO 20170526
- International Announcement: WO2017/205709 WO 20171130
- Main IPC: C07D403/10
- IPC: C07D403/10 ; C07D401/10 ; C07D403/14 ; C07D471/04 ; C07D487/04

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
Public/Granted literature
- US20190152956A1 TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK Public/Granted day:2019-05-23
Information query